Diskontinuering på grund af bivirkninger var 4. 5% (behandlingsnaive patienter) og 9% (behandlingserfarne patienter) over en periode på 48 uger.
Discontinuation due to adverse reactions was 4.5% (naïve patients) and 9% (experienced patients) over a 48 week period.